Abstract. MicroRNAs (miRNAs/miRs), including miR-181, are closely linked to the development and progression of glioblastoma. However, the function of miR-181 in glioblastoma has not been fully clarified. The aim of the present study was to investigate the role of miR-181 in glioblastoma. miR-181 was revealed to be downregulated in glioblastoma tissues and cell lines, and associated with poor prognosis in patients with glioblastoma. Overexpression of miR-181 inhibited glioblastoma cell proliferation, invasion and migration, arrested glioblastoma cell cycle in the G1 phase and induced glioblastoma cell apoptosis. miR-181 was demonstrated to decrease expression of C-C motif chemokine ligand 8 (CCL8) by directly interacting with its 3'-untranslated region. Overexpression of CCL8 inversely reversed the proliferation, invasion and migration-promoting effects of miR-181 in glioblastoma cells. Furthermore, CCL8 was upregulated in glioblastoma tissues and was negatively correlated with miR-181 expression. These results indicate that miR-181 is a potential molecular biomarker or therapeutic target in the clinical management of glioblastoma.
Introduction
Glioblastoma is the most common primary brain malignancy in adults, with an average annual incidence of ~3-10 in every 100,000 adults in the United States (1, 2) . Glioblastoma is defined as any tumor that is produced by glial cells or precursor cells, including astrocytoma, glioblastoma, ependymoma, mixed glioblastoma, and other rare histologies (3) . Grade IV glioblastomas have a poor prognosis, with a median survival time of 14.6-16 months and a 5-year survival rate of 3.4% (4, 5) . The standard first-line treatment for glioblastoma involves a variety of modalities, including surgical resection, radiotherapy and temozolomide-adjuvant chemotherapy (6) . Despite surgical resection and chemoradiation, tumors in almost all patients are likely to relapse, with a 2-year survival rate of only 26% following relapse (7) . There is currently no standard and uniform management method for recurrent glioblastoma. Therefore, the search for novel glioblastoma treatment pathways is particularly important. In recent years, with the development of molecular biology techniques, tumor-related genetic research has increased (8) . At present, gene therapies and molecular-targeted drugs are a novel area of study (9, 10) . The most important aspect of these treatments is identifying a specific molecular therapy target for different tumors.
microRNAs (miRNAs/miRs) have been identified as promising therapeutic targets in a number of types of cancer (11, 12) . miRNAs are short endogenous single-stranded RNA molecules that transcriptionally inhibit gene expression by targeting 3'-untranslated regions (3'-UTRs) of messenger RNAs (mRNAs) by binding to complementary sequences (13, 14) . miRNAs regulate a number of important cellular functions, including angiogenesis, proliferation, apoptosis and invasion, and are deregulated in numerous types of cancer (15) . A growing body of research indicates that miRNAs regulate the expression of chemokines, further effecting disease progression and prognosis (16) . miRNA-181 has been found to inhibit the progression of cervical cancer by targeting a transcription factor, yin-yang-1 (17, 18) . The expression of miR-181 and its impact on CCL8 in the progression of glioblastoma has not been studied.
The present study aimed to evaluate the potential of miRNA-181 and CLL8 as biomarkers or treatment targets in glioblastoma by investigating their expression in patients, and to determine the effects of altered miRNA-181 and CCL8 expression in glioblastoma cell lines. 
Materials and methods

Patient tissues.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA from all samples and cell lines was extracted using TRIzol ® (Invitrogen; Thermo Fisher Scientific, Inc.). Isolated RNA was reverse-transcribed using MultiScribe reverse transcriptase (Applied Biosystems; Thermo Fisher Scientific, Inc). Briefly, samples containing l µg total RNA were incubated with 1 µl gDNA Eraser, 2 µl 5X gDNA eraser buffer and RNase free dH 2 O at 42˚C for 2 min. After adding the enzyme mix, the reaction was incubated at 37˚C for 15 min. cDNA was diluted and stored at -20˚C prior to use. mRNA expression was detected with SYBR ® Premix Ex Taq II (Takara Biotechnology Co., Ltd., Dalian, China). The PCR primers were designed as follows: miR-181, forward 5'-AAC ATT CAA CGC TGT CGG TGA AGT-3', reverse 5'-ACT TCA CCG ACA GCG TTG AAT GTT-3'; U6, forward 5'-CTC GCT TCG GCA GCA CA-3' , reverse 5'-AAC GCT TCA CGA ATT TGC GT-3'; CCL-8 forward 5'-AGA TGA AGG TTT CTG CAG CGC-3', reverse 5'-TGG AAA CTG AAT CTG GCT GAG-3'; and GAPDH, forward 5'-GCA CCG TCA AGG CTG AGA AC-3' and reverse 5'-TGG TGA AGA CGC CAG TGGA-3' . RT-qPCR reactions were performed as follows: 95˚C for 10 min followed by 40 cycles of 95˚C for 25 sec and 60˚C for 30 sec. The relative expression levels of miR-181 and CCL-8 relative to GAPDH and U6 were calculated using the relative quantification 2 -ΔΔCq method (19) . Each sample was assayed in triplicates. The high and low expression of miR-181 was defined according to the average expression levels of miR-181 in patients with glioblastoma.
Western blot analysis. Total protein was extracted from the tissues and cells using radioimmunoprecipitation lysis buffer (Beyotime Institute of Biotechnology, Jiangsu, China) and separated using SDS-PAGE (10% gel), and then transferred to polyvinylidene difluoride membranes. The membranes were then incubated with 5% non-fat milk in Tris-buffered saline (TBS; 20 mM Tris-HCl, pH 7.5, 150 mM NaCl) containing 0.1% Tween 20 at room temperature. Subsequently, the membranes were incubated at room temperature with rabbit antibodies against CCL-8 (cat. no. ab39625; 1:500; Abcam, Cambridge, UK;) and GAPDH (cat. no. sc-47724; 1:500; Santa Cruz, Biotechnology, Inc., Dallas, TX, USA) overnight at 4˚C. Membranes were washed with TBST and incubated at room temperature with horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (cat. no. 7074; 1:5,000; Cell Signaling Technology, Inc., Danvers, MA, USA) for 40 min. Protein bands were detected by enhanced chemiluminescence (ECL) using Pierce ECL Western Blot Substrate (Thermo Fisher Scientific, Inc.) and exposed to an X-ray film using an ECL detection system (Thermo Fisher Scientific, Inc.). GAPDH served as a loading control. All assays were performed in triplicate.
Cell proliferation assay. A total of ~1x10 3 cells/well were cultured in 96-well plates and a Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan) was used to determine proliferation in each treatment group (6 wells per group) and in the blank controls. Cells were incubated with 10 µl CCK-8 at different time points (0, 24, 48 and 72 h) for 3 h at 37˚C and 5% CO 2 . The absorbance value at 450 nm was measured. The cell growth curves were plotted using the absorbance value at each time point. All assays were performed in triplicate.
Migration and invasion assay. Transwell chambers (24-wells; Corning Inc., Corning, NY, USA) were used to evaluate the migratory and invasive ability of glioblastoma cells. Transfected U87 and A172 cells in DMEM were added to the top chambers of the Transwell plate that were pre-coated with Matrigel (BD Biosciences, San Jose, CA, USA) for the invasion assay, and all other steps were identical. A total of 4x10 4 transfected cells without FBS were placed in the top chamber, and the bottom chamber was filled with 20% FBS. The cells were incubated at 37˚C for 24 h to allow migration or invasion through the membrane. The cells were then stained at room temperature with crystal violet (Beyotime Institute of Biotechnology, Shanghai, China) for 10 min. All assays were performed in triplicates.
Flow cytometry. Cells were cultured in 6-well plates at a concentration of 3x10 5 cells/well. Cells were washed with PBS and harvested with 0.25% trypsin without EDTA. Cells were then washed with PBS and stained with 5 µl Annexin V-fluorescein isothiocyanate (BD Biosciences) and 5 µl propidium iodide (BD Biosciences) for 15 min at room temperature in the dark according to the manufacturer's instructions. Data acquisition and analyses were performed on a BD FACSCalibur flow cytometer (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) using CellQuest software (version 5.2.1; BD Biosciences). All assays were performed in triplicate.
Statistical analysis. Data are shown as the mean ± standard deviation where applicable. Graphpad Prism (version 5.0; Graphpad Software Inc., La Jolla, CA, USA) was used for all statistical analysis. The differences between groups were evaluated by one way analysis of variance followed by Dunnett's test. Kaplan-Meier analysis and a log-rank test were used to compare patient survival. The correlation between the expression levels of miR-181 and CCL8 was assessed using Spearman's correlation analysis. P<0.05 was considered to indicate a statistically significant difference.
Results
miR-181 is downregulated in patients with glioblastoma and is associated with poor prognosis.
Expression of miR-181 in glioblastoma and adjacent tissues was detected using RT-qPCR. miR-181 expression in glioblastoma tissues was significantly decreased compared with that in adjacent tissues (Fig. 1A) , and the expression of miR-181 in glioblastoma with tumor diameter ≥5 cm was decreased compared with that in glioblastoma with tumor diameter <5 cm (Fig. 1B) . The expression of miR-181 in patients with different diagnostic grades was also evaluated. The expression of miR-181 in patients with grade III and IV glioblastoma was significantly lower compared with that in patients with grade II, and the expression of miR-181 in patients with grade IV glioblastoma was significantly lower compared with that in patients with grade III (Fig. 1C) . The patient group with low expression of miR-181 had a significantly lower survival rate compared with the group with high expression of miR-181 (Fig. 1D) . The results indicate that decreased expression of miR-181 is associated with poor prognosis.
Overexpression of miR-181 inhibited cell proliferation, invasion and migration in glioblastoma cell lines. The expression of miR-181 in human glioblastoma cell lines U251, A172 and U87, and normal human astrocytes NHA was detected by RT-qPCR. The expression of miR-181 in glioblastoma cell lines was significantly lower compared with that in normal human astrocytes NHA cells (Fig. 2A) . Following transfection of A172 and U87 cells with miR-181 mimic, miR-181 expression was significantly increased compared with that in cells transfected with miR-NC (Fig. 2B) . The effect of miR-181 on proliferation in glioblastoma cells, was investigated using the CCK-8 assay. The proliferation of A172 and U87 cells transfected with miR-181 was decreased compared with that of cells transfected with miR-NC ( Fig. 2C and D) . A Transwell assay revealed that the ability of A172 and U87 cells transfected with miR-181 to invade or migrate across a membrane was decreased compared with that of cells transfected with miR-NC ( Fig. 2E-H) . The results indicate that upregulation of miR-181 inhibits glioblastoma cell growth, invasion and migration.
Overexpression of miR-181 arrested cell cycle in the G1 phase and induced cell apoptosis in glioblastoma cell lines.
The effects of overexpression of miR-181 on cell cycle and apoptosis in glioblastoma cell was evaluated. The cell cycle was significantly shifted from S phase to G1 phase in U87 and A172 cells transfected with miR-181 compared with those transfected with miR-NC (Fig. 3A-D) . The percentage of cells in the G1 phase was increased and the percentage in the S phase was decreased in the miR-181-overexpressing groups. Overexpression of miR-181 promoted apoptosis in U87 (Fig. 3E and F ) and A172 cells (Fig. 3G and H) .
CCL8 is a target of miR-181.
The sequence alignment of miR-181 and the 3'-UTR of CCL-8 mRNA is presented in Fig. 4A . To further determine the interaction between miR-181 and CCL-8, luciferase vectors containing wide-type or mutated CCL8 3'-UTR were co-transfected into 293 cells (ATCC) with miR-NC or miR-181. The dual-luciferase reporter assay revealed that transfection with miR-181 reduced the activity of the luciferase reporter fused to the wild-type 3'-UTR of CCL-8, but did not suppress that of the reporter fused to the mutated version (Fig. 4B) . Following transfection with miR-181, protein and mRNA expression of CCL8 in U87 and A172 cells was decreased compared to those of cells transfected with miR-NC (Fig. 4C and D) . Following transfection of A172 and U87 cells with pcDNA-CCL8, CCL8 mRNA expression was significantly higher compared with cells that were transfected with pcDNA (Fig. 4E) . The results indicated that CCL8 was a direct target of miR-181 and overexpression of miR-181 reduced the expression of CCL8.
Overexpression of CCL8 partially reversed the effects of miR-181 overexpression in glioblastoma cell lines.
To confirm that the effects of miR-181 on cell proliferation, invasion and migration are mediated by CCL8 downregulation, U87 and A172 cells were transfected with miR-NC, miR-181 and co-transfected with CCL8. Overexpression of CCL8 partially reversed the inhibition of proliferation by miR-181 in U87 and A172 cells (Fig. 5A and B) . The inhibition of invasion and migration by miR-181 in the two cell lines was also partially rescued by overexpression of CCL8 (Fig. 5C and D) . Flow cytometric analysis revealed that overexpression of CCL8 partially reversed the apoptotic effect of miR-181 in U87 and A172 cells (Fig. 5E and F) . These results suggested that miR-181 promoted glioblastoma cell proliferation, invasion and migration and inhibited apoptosis partially through downregulation of CCL8.
Expression of CCL8 in glioblastoma tissues was negatively correlated with miR-181 expression.
The expression of CCL8 in glioblastoma and adjacent tissues were detected by RT-qPCR. CCL8 expression in glioblastoma tissues was significantly higher compared with that in adjacent tissues (Fig. 5G ). Spearman's correlation analysis showed that CCL8 was negatively correlated with miR-181 expression (Fig. 5H) . The results further suggested that miR-181 may inhibit glioblastoma cell growth and induces apoptosis by directly targeting CCL8.
Discussion
In the present study, miR-181 expression was revealed to be low in glioblastoma tissue and associated with poor prognosis in patients with glioblastoma. Overexpression of miR-181 inhibited glioblastoma cell proliferation, invasion and migration and arrested glioblastoma cell cycle in the G1 phase and induced glioblastoma cell apoptosis. CCL8 was upregulated in glioblastoma tissues and was negatively correlated with miR-181 expression. CCL8 was confirmed as a direct target of miR-181 using a dual luciferase assay. In addition, overexpression of CCL8 reversed the inhibition of proliferation, invasion and migration and induction of apoptosis by miR-181 in glioblastoma cells. The results suggested that downregulated miR-181 may promote glioblastoma cell proliferation, invasion and migration and inhibit apoptosis partially through binding and inhibiting CCL8. miRNAs can regulate cell proliferation, invasion, migration, the cell cycle and apoptosis (20) , as well as regulating transcription through RNA polymerase, to impact tumor development (21, 22) . Previous studies indicated that aberrant expression of miRNAs has been identified in a number of types of cancer, including stomach, liver, colorectal, breast and cervical cancer, as well as glioma and others (23, 24) . miR-181 is an important miRNA that is involved in the development of multiple tumor types (25, 26) . miR-181 was found to regulate cisplatin-resistant non-small cell lung cancer via the PTEN/PI3K/AKT pathway (27) . In the present study, downregulation of miR-181 was identified in patients with glioblastoma, and was associated with poor prognosis. The detailed mechanism remains unknown and further research is required.
To explore the function of miR-181 in glioblastoma, the proliferation, invasion and migratory abilities of A172 and U87 cells transfected with miR-181 were investigated and found to be lower compared with cells transfected with miR-NC. In addition, the cell cycle was significantly shifted from S phase to G1 phase, and apoptosis was promoted in U87 and A172 cells transfected with miR-181, compared with cells transfected with miR-NC. Su et al (28) reported that miR-181 is aberrantly overexpressed in patients with acute myeloid leukemia and can inhibit granulocytic and macrophage-like differentiation by directly targeting and downregulating the expression of PRKCD, CTDSPL and CAMKK1.
CCL8 has been reported to be a CCR5 agonist with a similar affinity to the receptor as CCL3 (MIP-1a), which in combination with CCR5 stimulates receptor internalization and intracellular calcium release (29, 30) . It has been reported that in lung cancer, CCL8 further promotes tumor progression by recruiting CCR5+ Treg cells to the tumor site (27) . In patients with malignant melanoma, CCL8 also promotes tumorigenesis and progression (31) . At present, the expression of CCL8 in glioma tissue has not been explored, and its role in the progression of glioma and the corresponding molecular mechanisms remain unclear. In the present study, the dual-luciferase reporter assay indicated that miR-181 reduced the activity of the luciferase reporter fused to the 3'-UTR-WT of CCL-8 but did not suppress that of the reporter fused to the MUT version. Protein and mRNA expression of CCL8 were significantly decreased in U87 and A172 cells transfected with miR-181. These results suggest that CCL8 is a direct target of miR-181 and overexpression of miR-181 reduces the expression of CCL8.
The impact of miR-181 via CCL8 on cell proliferation, invasion and migration was further confirmed by overexpression of CCL8. U87 and A172 cells were co-transfected with miR-181 and CCL8. The results demonstrated that overexpression of CCL8 partially reversed the proliferation, invasion, migration and apoptosis effects of miR-181 in U87 and A172 cells. In addition, CCL8 expression was high in glioblastoma tissues and negatively correlated with miR-181 expression. The results further suggested that miR-181 inhibits glioblastoma cell growth and induces apoptosis by directly targeting CCL8.
In summary, the present study revealed that miR-181 was downregulated in glioblastoma and associated with poor prognosis. Overexpression of miR-181 inhibited proliferation, invasion and migration and induced apoptosis in glioblastoma cells by directly targeting CCL8. miR-181 may serve as a novel prognostic biomarker glioblastoma.
